ClinicalTrials.gg
RecruitingNCT07205887Super TuscanUpdated Oct 20, 2026

A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

A Phase 2 interventional study of Remigromig and Aflibercept 2.0 mg in Neovascular Age-Related Macular Degeneration (NVAMD) and Branch Retinal Vein Occlusion (BRVO), sponsored by EyeBiotech Ltd.. Recruiting at 55 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by EyeBiotech Ltd. (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 20, 2026Interventions changedTitle changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Retinal Vein Occlusion with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Retinal Vein Occlusion · United States.

Planned enrollment
21st of 90
160 · median 40
Started
2025
with 1 other
Phase 2
16 of 106
1 open now
Registered
102nd of 106
by date

Among the 106 studies in Retinal Vein Occlusion with a site in United States, this one is the 21st largest by planned enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 in phase 2, and was the 102nd registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

6 of the 106 studies in Retinal Vein Occlusion with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Retinal Vein Occlusion with a site in United States, or all of them as a file.
02

Study summary

EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).

The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of remigromig via IVT or a high dose of remigromig via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion.

All participants in the study will receive a total of 3 injections of remigromig into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.

Read the detailed description

EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).

The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of remigromig via IVT or a high dose of remigromig via IVT:

  • one cohort of 40 treatment naïve NVAMD participants will be randomized (1:1) to 1 of the 2 doses of remigromig (as monotherapy),
  • one cohort of 40 incomplete responder (IR) NVAMD participants will be randomized (1:1) to 1 of the 2 doses of remigromig (as monotherapy),
  • one cohort of 40 IR NVAMD participants will be randomized (1:1) to 1 of the 2 doses of remigromig, to be administered in combination with aflibercept 2.0 mg
  • one cohort of 40 treatment naïve BRVO participants will be randomized (1:1) to 1 of the 2 doses of remigromig (as monotherapy)

Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion.

All participants in the study will receive a total of 3 injections of remigromig into the study eye, spaced at 4 weeks apart. IR NVAMD participants in the combination therapy cohort will also receive an injection of aflibercept 2.0 mg in the study eye on Day 1.

All participants will be assessed for safety and efficacy at injection visits. Treatment naïve NVAMD participants and IR NVAMD participants in the monotherapy cohort will also return 2 weeks after each injection visit for safety and efficacy assessments. Depending on the cohort, participants will be evaluated every 2 weeks or every 4 weeks, including measurement of ETDRS BCVA, examination by slit-lamp biomicroscopy, fundoscopy, and SD-OCT. Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns. The Week 12 Visit will serve as the end of study visit for all participants.

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration (NVAMD)
  • Branch Retinal Vein Occlusion (BRVO)

Keywords

  • Neovascular Age-Related Macular Degeneration
  • Branch Retinal Vein Occlusion
  • NVAMD
  • BRVO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Key General Inclusion Criteria

  • Be willing and able to understand the study procedures and the risks involved and provide written before the first study-related activity

Key Neovascular Age-related Macular Degeneration (NVAMD)-specific Inclusion Criteria

  • Be ≥ 50 years of age
  • Have treatment naive subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or juxtafoveal/extrafoveal CNV with foveal involvement
  • For participants who are treatment naïve for NVAMD, the diagnosis must have been made within 21 days prior to the Day 1 study treatment

Key Incomplete Responder (IR) NVAMD-specific Inclusion Criteria

  • Be ≥ 50 years of age
  • Have subfoveal CNV secondary to AMD or juxtafoveal/extrafoveal CNV with foveal involvement at initial screening
  • For participants who are treatment experienced for NVAMD, the diagnosis must have been made within 90 days prior to the Screening Visit 2

Key Branch Retinal Vein Occlusion (BRVO)-specific Inclusion Criteria

  • Be diagnosed with BRVO in the study eye
  • Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of BRVO
  • Be treatment naïve with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of Screening

Exclusion criteria

Exclusion Criteria:

Key General Exclusion Criteria

  • Pregnant or breastfeeding
  • History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
  • Have had Yttrium-Aluminum Garnet (YAG) laser capsulotomy in the study eye within 90 days of Screening
  • Currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)

Key NVAMD-specific Exclusion Criteria

  • Have had previous thermal subfoveal laser therapy in the study eye
  • Have had previous photodynamic therapy with Visudyne in the study eye

Key BRVO-specific Exclusion Criteria

  • Have macular edema in the study eye considered to be secondary to a cause other than BRVO (eg, diabetic macular edema, NVAMD, Irvine-Gass syndrome)
  • Have active iris or angle neovascularization or neovascular glaucoma in the study eye
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Treatment Naïve NVAMD - Low Dose Remigromig

    Treatment Naïve NVAMD Cohort - Low Dose Remigromig (50 μL)

    Drug: Remigromig

  • Experimental
    Treatment Naïve NVAMD - High Dose Remigromig

    Treatment Naïve NVAMD Cohort - High Dose Remigromig (50 μL)

    Drug: Remigromig

  • Experimental
    IR NVAMD - Low Dose Remigromig

    Incomplete Responder (IR) NVAMD Cohort - Low Dose Remigromig (50 μL)

    Drug: Remigromig

  • Experimental
    IR NVAMD - High Dose Remigromig

    Incomplete Responder (IR) NVAMD Cohort - High Dose Remigromig (50 μL)

    Drug: Remigromig

  • Experimental
    IR NVAMD - Low Dose Remigromig in combination with Aflibercept 2.0 mg

    Incomplete Responder (IR) NVAMD Cohort - Low Dose Remigromig (50 μL) in combination with Aflibercept 2.0 mg

    Drug: Remigromig · Drug: Aflibercept 2.0 mg

  • Experimental
    IR NVAMD - High Dose Remigromig in combination with Aflibercept 2.0 mg

    Incomplete Responder (IR) NVAMD Cohort - High Dose Remigromig (50 μL) in combination with Aflibercept 2.0 mg

    Drug: Remigromig · Drug: Aflibercept 2.0 mg

  • Experimental
    Treatment Naïve BRVO - Low Dose Remigromig

    Treatment Naïve BRVO Cohort - Low Dose Remigromig (50 μL)

    Drug: Remigromig

  • Experimental
    Treatment Naïve BRVO - High Dose Remigromig

    Treatment Naïve BRVO Cohort - High Dose Remigromig (50 μL)

    Drug: Remigromig

Interventions

  • Remigromig is a humanized antibody formulated for intravitreal administration

    Also known as: Restoret, EYE103

  • Aflibercept 2.0 mg is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with Neovascular Age-Related Macular Degeneration (NVAMD). Aflibercept 2.0 mg is only administered to 2 cohorts of Incomplete Responders (IR) with NVAMD in combination with Low Dose or High Dose Remigromig.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Best-Corrected Visual Acuity measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart

    Change from baseline in Best-Corrected Visual Acuity measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart

    Time frame: Week 12

Secondary outcomes

  1. Changes in retinal central subfield thickness (CST) based on spectral domain optical coherence tomography (SDOCT)

    Changes in retinal central subfield thickness (CST) based on spectral domain optical coherence tomography (SDOCT)

    Time frame: Duration of the study, through Week 12

  2. Changes in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart

    Changes in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart

    Time frame: Duration of the study, through Week 12

07

Study locations

55 of 55 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2028, 33 months after the start.

Of 14 phase 2 interventional studies under Retinal Vein Occlusion, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 29. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 3, 2025
StartActual
Sep 12, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Changed EYE103→Remigromig. Arm changed Treatment Naïve NVAMD - Low Dose EYE103→Treatment Naïve NVAMD - Low Dose Remigromig; Treatment Naïve NVAMD - High Dose EYE103→Treatment Naïve NVAMD - High Dose Remigromig; IR NVAMD - Low Dose EYE103→IR NVAMD - Low Dose Remigromig; IR NVAMD - High Dose EYE103→IR NVAMD - High Dose Remigromig; IR NVAMD - Low Dose EYE103 in combination with Aflibercept 2.0 mg→IR NVAMD - Low Dose Remigromig in combination with Aflibercept 2.0 mg; IR NVAMD - High Dose EYE103 in combination with Aflibercept 2.0 mg→IR NVAMD - High Dose Remigromig in combination with Aflibercept 2.0 mg; Treatment Naïve BRVO - Low Dose EYE103→Treatment Naïve BRVO - Low Dose Remigromig; Treatment Naïve BRVO - High Dose EYE103→Treatment Naïve BRVO - High Dose Remigromig
Oct 20, 2026
Title
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Interventions Changed EYE103→Remigromig. Arm changed Treatment Naïve NVAMD - Low Dose EYE103→Treatment Naïve NVAMD - Low Dose Remigromig; Treatment Naïve NVAMD - High Dose EYE103→Treatment Naïve NVAMD - High Dose Remigromig; IR NVAMD - Low Dose EYE103→IR NVAMD - Low Dose Remigromig; IR NVAMD - High Dose EYE103→IR NVAMD - High Dose Remigromig; IR NVAMD - Low Dose EYE103 in combination with Aflibercept 2.0 mg→IR NVAMD - Low Dose Remigromig in combination with Aflibercept 2.0 mg; IR NVAMD - High Dose EYE103 in combination with Aflibercept 2.0 mg→IR NVAMD - High Dose Remigromig in combination with Aflibercept 2.0 mg; Treatment Naïve BRVO - Low Dose EYE103→Treatment Naïve BRVO - Low Dose Remigromig; Treatment Naïve BRVO - High Dose EYE103→Treatment Naïve BRVO - High Dose Remigromig
    Title A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07205887
Lead sponsor
EyeBiotech Ltd.
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Sep 12, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Charles Miller, MD PhD
Contact
ClinicalInquiries@eyebiotech.com
212-914-0127
Charles Miller, MD PhD
study director · EyeBiotech Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remigromig

Start the discussion